KR910018038A - 원발성 흉막암의 치료를 위한 제약 조성물 제조용 인체 인터루킨 2활성 함유 폴리펩티드의 용도 - Google Patents

원발성 흉막암의 치료를 위한 제약 조성물 제조용 인체 인터루킨 2활성 함유 폴리펩티드의 용도 Download PDF

Info

Publication number
KR910018038A
KR910018038A KR1019900008407A KR900008407A KR910018038A KR 910018038 A KR910018038 A KR 910018038A KR 1019900008407 A KR1019900008407 A KR 1019900008407A KR 900008407 A KR900008407 A KR 900008407A KR 910018038 A KR910018038 A KR 910018038A
Authority
KR
South Korea
Prior art keywords
use according
manufacture
pharmaceutical composition
treatment
human interleukin
Prior art date
Application number
KR1019900008407A
Other languages
English (en)
Other versions
KR0165674B1 (ko
Inventor
브랑델리 모
랑도 다니엘
Original Assignee
로우셀-우크라프
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로우셀-우크라프 filed Critical 로우셀-우크라프
Publication of KR910018038A publication Critical patent/KR910018038A/ko
Application granted granted Critical
Publication of KR0165674B1 publication Critical patent/KR0165674B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

원발성 흉막암의 치료를 위한 제약 조성물 제조용 인체 인터루킨 2활성 함유 폴리펩티드의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 원발성 흉막암의 치료를 목적으로 하는 제약 조성물 제조용 인체 인터추킨 2의 활성을 갖는 폴리펩티드의 용도.
  2. 제1항에 있어서, 흉막암이 중피종인 것이 특징인 용도.
  3. 제2항에 있어서, 인체IL2의 활성을 갖는 폴리펩티드가 정제된 재조합 IL2의 인 거이 특징인 용도.
  4. 제3항에 있어서, IL2가 환원 형태의 비글리코실화 재조합 IL2인 것이 특징인 용도.
  5. 제3항 또는 제4항에 있어서, IL2를 1회 2-25X106U/M2의 주사용량으로 흉막내 경로로 투여하는 것을 특징인 용도.
  6. 제5항에 있어서, IL2 를 15X106U/M2의 일일 용량으로 투여하는 것이 특징인 용도
  7. 제6항에 있어서, IL2를 5일 연속 주기마다 투여하는 것이 특징인 용도.
  8. 제7항에 있어서, IL2를 적어도 2호의 비연속 주기를 거치도록 반복 투여하는 것이 특징인 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900008407A 1990-04-17 1990-06-08 원발성 흉막암의 치료를 위한 제약 조성물 KR0165674B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR90-04895 1990-04-17
FR9004895A FR2660863B1 (fr) 1990-04-17 1990-04-17 Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.

Publications (2)

Publication Number Publication Date
KR910018038A true KR910018038A (ko) 1991-11-30
KR0165674B1 KR0165674B1 (ko) 1999-01-15

Family

ID=9395818

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900008407A KR0165674B1 (ko) 1990-04-17 1990-06-08 원발성 흉막암의 치료를 위한 제약 조성물

Country Status (13)

Country Link
US (1) US5219565A (ko)
EP (1) EP0452598B1 (ko)
JP (1) JP2848922B2 (ko)
KR (1) KR0165674B1 (ko)
AT (1) ATE97575T1 (ko)
AU (1) AU631649B2 (ko)
CA (1) CA2018630A1 (ko)
DE (1) DE69004794T2 (ko)
DK (1) DK0452598T3 (ko)
FR (1) FR2660863B1 (ko)
HU (1) HU205261B (ko)
OA (1) OA09213A (ko)
ZA (1) ZA904353B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668368B1 (fr) * 1990-10-30 1995-03-10 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement des tumeurs malignes epitheliales.
FR2671728B1 (fr) * 1991-01-17 1995-01-20 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des pneumathorax.
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5419900A (en) * 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
ES2484966T3 (es) 2000-04-12 2014-08-12 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
US20030143191A1 (en) * 2001-05-25 2003-07-31 Adam Bell Chemokine beta-1 fusion proteins
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0031539B1 (en) * 1979-12-28 1987-03-25 International Business Machines Corporation Voltage distribution system of an lsi chip
FR2635527B1 (fr) * 1988-07-28 1992-06-12 Roussel Uclaf Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament

Also Published As

Publication number Publication date
DK0452598T3 (da) 1994-01-17
ATE97575T1 (de) 1993-12-15
KR0165674B1 (ko) 1999-01-15
CA2018630A1 (fr) 1991-10-17
FR2660863A1 (fr) 1991-10-18
AU631649B2 (en) 1992-12-03
AU5693590A (en) 1991-11-21
ZA904353B (en) 1991-08-28
US5219565A (en) 1993-06-15
EP0452598B1 (fr) 1993-11-24
EP0452598A1 (fr) 1991-10-23
HUT56721A (en) 1991-10-28
FR2660863B1 (fr) 1994-01-21
JPH045241A (ja) 1992-01-09
DE69004794D1 (de) 1994-01-05
HU205261B (en) 1992-04-28
JP2848922B2 (ja) 1999-01-20
HU903769D0 (en) 1990-11-28
DE69004794T2 (de) 1994-04-14
OA09213A (fr) 1992-06-30

Similar Documents

Publication Publication Date Title
EP0564739A3 (ko)
ATE72991T1 (de) Nasale verabreichung von arzneimitteln.
KR950702841A (ko) 인터루킨-4 및/또는 인터루킨-10을 함유하는 약제학적조성물
GR3017282T3 (en) Novel arylpyridazines, their manufacture, use and medicaments containing them.
IE862554L (en) Pharmaceutical compositions
IL87621A0 (en) Conjugates of cytokines with immunoglobulins,their preparation and pharmaceutical compositions containing them
FI862011A (fi) Terapeutiska nukleosider.
DK502888A (da) Anvendelse af azithromycin og derivater deraf til fremstilling af antiprotozoale laegemidler
FI941771A (fi) Tehostettu ihonläpäisyjärjestelmä lääkeaineiden parannettua paikallista antoa varten
KR910018038A (ko) 원발성 흉막암의 치료를 위한 제약 조성물 제조용 인체 인터루킨 2활성 함유 폴리펩티드의 용도
MY108146A (en) Medicaments for treating inflammatory conditions or for analgesia
SE8404065D0 (sv) Novel biologically active compounds
SE8600632D0 (sv) Novel pharmaceutical composition
DE3686022D1 (de) Monosaccharide enthaltende zusammensetzung zum heilen von wunden.
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
DE69402576T2 (de) Cytotoxische und antivirale Verbindung
FR2362849A1 (fr) Nouvelles heterocyclo-omega-pentanorprostaglandines aryliques substituees en position 2 et medicament les contenant
KR920014480A (ko) 기흉 치료용 제약 조성물을 제조하기 위한 인간 인터류킨 2의 활성을 갖는 폴리펩티드의 용도
ES2061496T3 (es) Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.
KR910009280A (ko) 원발성 흉막암 치료용 제약 조성물의 제조에 있어서 감마 인터페론 활성을 갖는 폴리펩티드의 용도
KR890017363A (ko) 스트로빌루린 유도체, 이들의 제법 및 용도
DK0572557T3 (da) Anvendelse af topotecan til fremstilling af et lægemiddel til anvendelse ved behandling af kræft i æggestokkene
NO174963C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 8-fluorantracyklinglucosider
FI853506A0 (fi) Nya antibioter, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska kompositioner.
IT1230053B (it) Composizione per l'aumento del guadagno di peso.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee